Dettol Antiseptic Disinfectant 4.8 % w/v Concentrate for Cutaneous Solution

  • Name:

    Dettol Antiseptic Disinfectant 4.8 % w/v Concentrate for Cutaneous Solution

  • Company:
    info
  • Active Ingredients:

    Chloroxylenol

  • Legal Category:

    Supply through general sale

Summary of Product Characteristics last updated on medicines.ie: 5/4/2018
print

Print ViewKeyword Search SmPC

Reckitt Benckiser Ireland Limited

Reckitt Benckiser Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Bonjela Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Bonjela Teething Gel Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Dettol Antiseptic Disinfectant 4.8 % w/v Concentrate for Cutaneous Solution Active Ingredients Chloroxylenol
Medicine Name Disprin Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name Disprin Direct 300mg Orodispersible Tablets Active Ingredients Aspirin
Medicine Name Disprin Extra Strength Active Ingredients Acetylsalicylic Acid
Medicine Name E45 Cream Active Ingredients Anhydrous Lanolin, Light Liquid Paraffin, White Soft Paraffin
Medicine Name Fybogel Citrus Active Ingredients Ispaghula Husk
Medicine Name Fybogel Mebeverine Active Ingredients Ispaghula Husk, Mebeverine Hydochloride
Medicine Name Fybogel Orange 3.5g Granules Active Ingredients Ispaghula Husk
Medicine Name Gaviscon Advance Oral Suspension Active Ingredients Potassium hydrogen carbonate, Sodium Alginate
Medicine Name Gaviscon Advance Tablets Active Ingredients Potassium Bicarbonate, Sodium Alginate
Medicine Name Gaviscon Extra Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Oral Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Oral Suspension 300ml Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Infant Active Ingredients Magnesium Alginate, Sodium Alginate
Medicine Name Gaviscon Liquid - Peppermint Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Liquid Aniseed Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Peppermint Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Hydrogen Carbonate
Medicine Name Gaviscon Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Hc45 Hydrocortisone Acetate 1% w/w Cream Active Ingredients Hydrocortisone Acetate
Medicine Name Lemsip Chesty Cough 50 mg/5 ml Oral Solution Active Ingredients Guaifenesin
Medicine Name Lemsip Cold & Flu Capsules with Caffeine Active Ingredients Caffeine, Paracetamol
Medicine Name Lemsip Cold & Flu Headcold 500mg Powder for Oral Solution Active Ingredients Paracetamol
Medicine Name Lemsip Cold & Flu Hot Lemon 500mg Powder for Oral Solution Active Ingredients Paracetamol
1 - 0 of 64 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 5 April 2018 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose

Free text change information supplied by the pharmaceutical company

Section 4.2 Posology and Method of Administration:
Reworded as follows:-
Posology:
Adults: Wash the affected area with product at 5% dilution (50ml product in 1 litre water)
Paediatric population:  Children over the age of 1 year - as above of adult.  Children under the age of 1 year - not for use in children under one year of age.
Method of Administration:
Apply topically to relevant area as requested.  Do not use undiluted.

Section 4.3 Contraindications:
Reworded as follows:-
Hypersensitivity to chloroxylenol or any of the excipients listed in Section 6.1
Do not use on eczematous conditions.  Not for use on children under one year of age

Section 4.4 Special warnings and special precautions for use:
Addition of the following wording:-Not for use around eyes, ears, nose or mouth.  If contact is made, wash thoroughly with cold water.  Not for use on large areas of the body or on sensitive skin.

Section 4.6 Fertility, Pregnancy & Lactation:
Reworded as follows:-
Pregnancy:  No effects during pregnancy are anticipated, since systemic exposure from topical chloroxylenol use is negligible.  As with all medicines, this product should be used with caution during pregnancy.
Breast-feeding:  Is it unknown whether chloroxylenol or its metabolites are excreted in human milk.  A risk to the newborns/infants cannot be excluded.  Application of the product to the breast is not recommended during breast-feeding.
Lactation: No data on human fertility are available.

Section 4.8 Undesirable Effects:
Addition of frequencies & MEDdra table
Addition of paragraph on how to Report a Suspected Adverse Event.

Section 4.9 Overdose:
 Reworded as follows:
Symptoms:  Topical application of undiluted chloroxylenol can cause skin burning.
Oral ingestion may result in pharyngeal erosion, laryngeal oedema, stomatitis, bradycardia, hypotension, renal failure and CNS depression.  Pulmonary aspiration following ingestion may result in pheumonia, acute respiratory distress syndrome and cardiorespiratory arrest.  There have been reported of deaths by excessive consumption.
Management:  In the case of accidental ingestion or excess exposure, wash out mouth and drink plenty of water or milk and contact your doctor immediately.  Careful observation of airway patency for 24-48 hours should be made post-ingestion.

Updated on 5 April 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.2 Posology and Method of Administration:
Reworded as follows:-
Posology:
Adults: Wash the affected area with product at 5% dilution (50ml product in 1 litre water)
Paediatric population:  Children over the age of 1 year - as above of adult.  Children under the age of 1 year - not for use in children under one year of age.
Method of Administration:
Apply topically to relevant area as requested.  Do not use undiluted.

Section 4.3 Contraindications:
Reworded as follows:-
Hypersensitivity to chloroxylenol or any of the excipients listed in Section 6.1
Do not use on eczematous conditions.  Not for use on children under one year of age

Section 4.4 Special warnings and special precautions for use:
Addition of the following wording:-Not for use around eyes, ears, nose or mouth.  If contact is made, wash thoroughly with cold water.  Not for use on large areas of the body or on sensitive skin.

Section 4.6 Fertility, Pregnancy & Lactation:
Reworded as follows:-
Pregnancy:  No effects during pregnancy are anticipated, since systemic exposure from topical chloroxylenol use is negligible.  As with all medicines, this product should be used with caution during pregnancy.
Breast-feeding:  Is it unknown whether chloroxylenol or its metabolites are excreted in human milk.  A risk to the newborns/infants cannot be excluded.  Application of the product to the breast is not recommended during breast-feeding.
Lactation: No data on human fertility are available.

Section 4.8 Undesirable Effects:
Addition of frequencies & MEDdra table
Addition of paragraph on how to Report a Suspected Adverse Event.

Section 4.9 Overdose:
 Reworded as follows:
Symptoms:  Topical application of undiluted chloroxylenol can cause skin burning.
Oral ingestion may result in pharyngeal erosion, laryngeal oedema, stomatitis, bradycardia, hypotension, renal failure and CNS depression.  Pulmonary aspiration following ingestion may result in pheumonia, acute respiratory distress syndrome and cardiorespiratory arrest.  There have been reported of deaths by excessive consumption.
Management:  In the case of accidental ingestion or excess exposure, wash out mouth and drink plenty of water or milk and contact your doctor immediately.  Careful observation of airway patency for 24-48 hours should be made post-ingestion.

Updated on 5 April 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through general sale

Updated on 24 August 2012 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Updated section 6.5 of the SmPC to remove reference to "Glass bottles with hard plastic screw cap"

Updated on 24 August 2012 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through general sale

Updated on 24 August 2012 PIL

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Free text change information supplied by the pharmaceutical company

Updated section 6.5 of the SmPC to remove reference to "Glass bottles with hard plastic screw cap"

Updated on 15 June 2012 PIL

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation

Free text change information supplied by the pharmaceutical company

To correct date of first authorisation

Updated on 15 June 2012 SmPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

To correct date of first authorisation

Updated on 19 October 2009 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 9 - Date of renewal of authorisation

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 1 - addition of strength and pharmaceutical form to name
Section 9 - date of last renewal updated

Updated on 19 October 2009 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 9 - Date of renewal of authorisation

Free text change information supplied by the pharmaceutical company

Section 1 - addition of strength and pharmaceutical form to name
Section 9 - date of last renewal updated

Updated on 10 May 2007 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Free text change information supplied by the pharmaceutical company

Section 7.  Change of address of Marketing Authorisation Holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.

Updated on 10 May 2007 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 7.  Change of address of Marketing Authorisation Holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.

Updated on 19 May 2005 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Supply through general sale

Updated on 19 May 2005 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 10 August 2004 PIL

Reasons for updating

  • New SPC for medicines.ie

Updated on 10 August 2004 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through general sale